Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Atazanavir (also called Latazanavir, Zrivada, Reyataz, BMS-232632) is an azapeptide and HIV-protease inhibitor that is used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents. In a cell-free assay, atazanavir inhibits HIV protease with a Ki value of 2.66 nM. It is used to treat human immunodeficiency virus infection, just like other antiretrovirals. When compared to other PIs, atazanavir can be administered once daily and has less of an impact on the patient's lipid profile. It is only used in conjunction with other HIV medications, just like other protease inhibitors.medications.
Targets |
CYP3; HIV-1
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C38H52N6O7
|
---|---|
Molecular Weight |
704.86
|
Exact Mass |
704.38975
|
Elemental Analysis |
C, 64.75; H, 7.44; N, 11.92; O, 15.89
|
CAS # |
198904-31-3
|
Related CAS # |
Atazanavir sulfate;229975-97-7;Atazanavir-d15;1092540-56-1;Atazanavir-d18;1092540-52-7;Atazanavir-d9;1092540-51-6;Atazanavir-d5;1132747-14-8;Atazanavir-d6;1092540-50-5
|
Appearance |
Solid powder
|
SMILES |
CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
|
InChi Key |
AXRYRYVKAWYZBR-GASGPIRDSA-N
|
InChi Code |
InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
|
Chemical Name |
methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
|
Synonyms |
Latazanavir; Zrivada; Reyataz; BMS-232632; BMS232632; BMS 232632; Atazanavir
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4187 mL | 7.0936 mL | 14.1872 mL | |
5 mM | 0.2837 mL | 1.4187 mL | 2.8374 mL | |
10 mM | 0.1419 mL | 0.7094 mL | 1.4187 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04121195 | Active Recruiting |
Drug: Dose escalation | HIV/AIDS Tuberculosis |
University of Liverpool | October 30, 2020 | Phase 2 Phase 3 |
NCT04022967 | Active Recruiting |
Drug: dolutegravir Drug: Lamivudine |
HIV-1-infection | ANRS, Emerging Infectious Diseases |
September 21, 2020 | Phase 3 |
NCT04468087 | Active Recruiting |
Drug: Atazanavir Drug: Placebo Atazanavir |
COVID-19 | Hospital do Coracao | February 15, 2021 | Phase 2 Phase 3 |
NCT03019783 | Completed | Drug: Atazanavir Other: Placebo |
HIV | Brigham and Women's Hospital |
December 2011 | Phase 2 Phase 3 |
NCT05680792 | Completed | Drug: Nitazoxanide Drug: Atazanavir/ritonavir |
Drug Interaction | Obafemi Awolowo University | September 10, 2020 | Not Applicable |